Analysts forecast that Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will announce earnings of ($0.17) per share for the current quarter, Zacks reports. Four analysts have issued estimates for Conatus Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.26) and the highest estimate coming in at ($0.12). Conatus Pharmaceuticals reported earnings per share of ($0.35) during the same quarter last year, which would suggest a positive year over year growth rate of 51.4%. The business is scheduled to report its next quarterly earnings results on Wednesday, March 21st.
Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Conatus Pharmaceuticals.
CNAT has been the topic of several recent analyst reports. Roth Capital initiated coverage on shares of Conatus Pharmaceuticals in a research note on Thursday. They set a “buy” rating and a $20.00 price objective on the stock. Zacks Investment Research lowered shares of Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, January 16th. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price target (down from $18.00) on shares of Conatus Pharmaceuticals in a report on Thursday, November 2nd. Finally, S&P Equity Research raised their price objective on shares of Conatus Pharmaceuticals from $5.02 to $5.69 in a report on Wednesday, January 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $13.67.
Hedge funds have recently made changes to their positions in the business. New York State Common Retirement Fund increased its stake in Conatus Pharmaceuticals by 156.4% during the 3rd quarter. New York State Common Retirement Fund now owns 24,100 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 14,700 shares during the period. Wells Fargo & Company MN increased its holdings in Conatus Pharmaceuticals by 77.4% in the 4th quarter. Wells Fargo & Company MN now owns 34,036 shares of the biotechnology company’s stock valued at $157,000 after buying an additional 14,848 shares during the period. Voya Investment Management LLC bought a new stake in Conatus Pharmaceuticals in the 2nd quarter valued at $101,000. Rhumbline Advisers bought a new stake in Conatus Pharmaceuticals in the 2nd quarter valued at $156,000. Finally, Bank of New York Mellon Corp increased its holdings in Conatus Pharmaceuticals by 17.3% in the 4th quarter. Bank of New York Mellon Corp now owns 215,843 shares of the biotechnology company’s stock valued at $997,000 after buying an additional 31,822 shares during the period. 38.77% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Anticipate Conatus Pharmaceuticals Inc (CNAT) Will Announce Earnings of -$0.17 Per Share” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/02/12/zacks-analysts-anticipate-conatus-pharmaceuticals-inc-cnat-will-announce-earnings-of-0-17-per-share.html.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.